Copeia Abstract / Cannabis Medicinalis
Systematic Review of Clinical Pharmacokinetics of THC Following Consumption of Different Cannabis Products.
A. Landschaft (1,2), D. Stepensky (3)
Boston Children’s Hospital, Boston, MA 02115
Copeia GmbH, Bergisch Gladbach, Germany D51469
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel 8410501
Introduction: THC-containing cannabis products are used for medicinal purposes by wide populations of patients. THC has been reported to have variable pharmacokinetics following consumption by different routes, which limits its clinical safety and effectiveness, and requires extensive titration and monitoring of patients that use cannabis products. There are substantial differences in the exposure to the THC and in the values of its pharmacokinetic parameters that were reported in different clinical trials.
Aims: To retrieve and assess the available clinical data on the pharmacokinetics of THC in human subjects or patients following consumption of different cannabis products.
Methods: Publications on clinical pharmacokinetics of THC were retrieved from the PubMed database, Cmax and AUC of THC and its metabolites, and subjects’ demographic data were retrieved according to the PRISMA guidelines. These data were summarized and analyzed to reveal the extent of the available data and its variability.
Results: We identified 39 publications that matched the search criteria and included quantitative data on Cmax and AUC of THC and its metabolites. Majority of the retrieved datasets were small (mean: 18.84, 95% CI [12.43, 25.25])),originated from young volunteers (25 datasets, mean: 29.55, 95% CI [26.73, 32.37]), mostly male, cannabis-naïve or with previous experience with cannabis. The investigated products were cigarette, inhaler vaporizer, and oral/oromucosal (31, 17, and 10 datasets, respectively). Cmax and AUC of THC and of its metabolites were highly variable, within the individual datasets, and between the datasets.
Conclusions: THC is characterized by high intersubject pharmacokinetic variability, following consumption of different cannabis products. The extent of intra-subject variability cannot be assessed based on the available data, and requires further investigation. THC pharmacokinetic data in patients are scarce, and no conclusions regarding the THC pharmacokinetic variability in relation to patients’ age, gender, genotype/phenotype, disease state, etc. can be made based on the available data. More rich pharmacokinetic THC data from clinical trials in patients with different diseases, and “real world” data are needed to reveal the extent of the inter- and intra-subject pharmacokinetic variability of THC and to identify the variability factors.
Keywords: THC, cannabis, pharmacokinetics, variability factors, systematic review.
This abstract is listed in the journal: «Medical Cannabis and Cannabinoids» (Karger Publishers, Basel, Switzerland) is the official journal of SSCM Swiss Society of Cannabis in Medicin and the SSCM-IACM IACM - International Association for Cannabinoid Medicines Cannabinoid Conference 2022. Cannabis Medicinalis
Cannabis Medicinalis
The 12th IACM Conference on Cannabinoids in Medicine & 1st SSCM Conference on Cannabis in Medicine took place on the 20th & 21st, of October 2022, at the Congress Centre in Basel, Switzerland, organized by the IACM (International Association for Cannabinoid Medicines) and SSCM (Swiss Working Group on Cannabinoids in Medicine).
Copeia's staff and advisory fellows have co-authored four research abstracts that were peer-reviewed by the scientific committee. We presented these at the poster session of the conference:
cannabismedicinalis.com
If you would like to learn more about Copeia, have questions or suggestions, please contact us by email and we will get back to you as soon as possible. We look forward to hearing from you.
Your Copeia team
Copeia’s digital health solutions evolve personalised treatment of cannabis patients
Copeia combines expertise from international cannabinoid research with practical knowledge of doctors, patients, pharmacies and producers.
Copeia is a software company based in Cologne and Berlin that develops AI-based products and workflow solutions to support medical cannabis care.